TVAX Biomedical Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $500K

  • Investors
  • 2

TVAX Biomedical General Information

Description

Developer of cell-based immunotherapies designed to treat aggressive solid cancers. The company's technology utilizes a dual-mechanism approach combining personalized cancer cell vaccination with activated killer T-cell therapy, enabling healthcare providers to target glioblastoma and other solid tumors through autologous cell processing that overcomes immune suppression and reduces treatment toxicity.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • PO Box 19311
  • Lenexa, KS 66285-9311
  • United States
+1 (913)
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Drug Discovery
Vertical(s)
Corporate Office
  • PO Box 19311
  • Lenexa, KS 66285-9311
  • United States
+1 (913)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

TVAX Biomedical Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC 27-Jun-2024 $500K Completed Clinical Trials - Phase 2
10. Secondary Transaction - Private Completed Clinical Trials - Phase 2
9. Grant 18-Oct-2022 Completed Clinical Trials - Phase 2
8. Later Stage VC 15-Mar-2016 Completed Clinical Trials - Phase 2
7. Later Stage VC 30-Mar-2015 Completed Clinical Trials - Phase 2
6. Later Stage VC 15-Apr-2013 Completed Clinical Trials - Phase 2
5. Later Stage VC 12-Dec-2012 Completed Clinical Trials - Phase 2
4. IPO 17-May-2012 Cancelled Clinical Trials - Phase 1
3. Later Stage VC 28-Apr-2011 $5.67M $7.67M Completed Clinical Trials - Phase 1
2. Later Stage VC 15-Dec-2010 $1.6M $2M Completed Clinical Trials - Phase 1
To view TVAX Biomedical’s complete valuation and funding history, request access »

TVAX Biomedical Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view TVAX Biomedical’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

TVAX Biomedical Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of cell-based immunotherapies designed to treat aggressive solid cancers. The company's technology utilizes a
Biotechnology
Lenexa, KS
4 As of 2026

Madison, WI
 

Plymouth Meeting, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

TVAX Biomedical Competitors (56)

One of TVAX Biomedical’s 56 competitors is Centrose, a Venture Capital-Backed company based in Madison, WI.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Centrose Venture Capital-Backed Madison, WI
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Aura Biosciences Formerly VC-backed Boston, MA
Allorion Therapeutics Venture Capital-Backed Natick, MA
Iovance Biotherapeutics Corporation San Carlos, CA
You’re viewing 5 of 56 competitors. Get the full list »

TVAX Biomedical Patents

TVAX Biomedical Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2010104836-A1 Infectious disease cellular immunotherapy Inactive 09-Mar-2009
DE-60032622-D1 Composition and method for cancer antigen immunotherapy Inactive 05-Oct-1999
DE-60032622-T2 Composition and method for cancer antigen immunotherapy Inactive 05-Oct-1999
ES-2279772-T3 Composition and method of antigenic antigenic immunotherapy. Inactive 05-Oct-1999
EP-1225870-A1 Composition and method of cancer antigen immunotherapy Active 05-Oct-1999 A61K40/11
To view TVAX Biomedical’s complete patent history, request access »

TVAX Biomedical Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

TVAX Biomedical Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
eGrowth Ventures Not-For-Profit Venture Capital Minority
FDA Orphan Other
To view TVAX Biomedical’s complete investors history, request access »

TVAX Biomedical Investments (1)

TVAX Biomedical’s most recent deal was a Joint Venture with V2ACT Therapeutics. The deal was made on 01-Jan-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
V2ACT Therapeutics 01-Jan-2019 Joint Venture Drug Discovery
To view TVAX Biomedical’s complete investments history, request access »

TVAX Biomedical FAQs

  • When was TVAX Biomedical founded?

    TVAX Biomedical was founded in 2004.

  • Where is TVAX Biomedical headquartered?

    TVAX Biomedical is headquartered in Lenexa, KS.

  • What is the size of TVAX Biomedical?

    TVAX Biomedical has 4 total employees.

  • What industry is TVAX Biomedical in?

    TVAX Biomedical’s primary industry is Biotechnology.

  • Is TVAX Biomedical a private or public company?

    TVAX Biomedical is a Private company.

  • What is TVAX Biomedical’s current revenue?

    The current revenue for TVAX Biomedical is .

  • How much funding has TVAX Biomedical raised over time?

    TVAX Biomedical has raised $14.6M.

  • Who are TVAX Biomedical’s investors?

    eGrowth Ventures and FDA Orphan have invested in TVAX Biomedical.

  • Who are TVAX Biomedical’s competitors?

    Centrose, Inovio Pharmaceuticals, Aura Biosciences, Allorion Therapeutics, and Iovance Biotherapeutics are some of the 56 competitors of TVAX Biomedical.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process